Nishiyama M
Nihon Geka Gakkai Zasshi. 1987 Feb;88(2):152-62.
Subrenal capsule assay (SRC assay) was investigated to evaluate the usefulness as an in vivo chemosensitivity test of anticancer agents. The pathological study on the growth of the implanted tumor and host response indicated that the assay had to be done by four-day assay. The analysis of the isotope incorporation into the implanted tumor supported this results. As determination of tumor sensitivity by the microscopic measurement showed the large standard deviation, the DNA and protein content was determined for the evaluation of sensitivity by percent inhibition of the DNA/protein content (%DNA/protein). Ninety five fresh tumor specimens were examined and evaluated by relative variation of the calculated tumor weight (delta TW/TW0), while 64 specimens by %DNA/protein. The evaluability rates using delta TW/TW0 and %DNA/protein were 84.2% and 87.5%, respectively. All over predictive accuracy between the clinical responses and the results of the assay evaluated by delta TW/TW0 was 78.6%, while 81.8% was obtained by %DNA/protein. From these results, the potential utility of SRC assay examined on 4 day for determining chemosensitivity by %DNA/protein seems to be beneficial for clinical use.
研究了肾包膜下测定法（SRC测定法），以评估其作为抗癌药物体内化学敏感性测试的实用性。对植入肿瘤生长和宿主反应的病理学研究表明，该测定法必须通过为期四天的测定来进行。对植入肿瘤中同位素掺入的分析支持了这一结果。由于通过显微镜测量确定肿瘤敏感性显示出较大的标准差，因此通过DNA/蛋白质含量的抑制百分比（%DNA/蛋白质）来测定DNA和蛋白质含量以评估敏感性。对95个新鲜肿瘤标本通过计算肿瘤重量的相对变化（δTW/TW0）进行检查和评估，而64个标本通过%DNA/蛋白质进行评估。使用δTW/TW0和%DNA/蛋白质的可评估率分别为84.2%和87.5%。通过δTW/TW0评估的临床反应与测定结果之间的总体预测准确率为78.6%，而通过%DNA/蛋白质获得的准确率为81.8%。从这些结果来看，通过%DNA/蛋白质在第4天进行的SRC测定法在确定化学敏感性方面的潜在实用性似乎对临床应用有益。
